EAM
IMVTU

Eventide Asset Management’s Immunovant, Inc. Units IMVTU Stock Holding History

Eventide Asset Management’s Portfolio IMVTU Stock Details IMVTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-680,000
Closed -$16.9M – 138
2019
Q4 		$16.9M Buy
+680,000
New +$14.6M 0.48% 65

Other funds holding IMVTU

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Eventide Asset Management's IMVTU Position: Q1 2020 in Review

Eventide Asset Management sold out of Immunovant, Inc. Units (IMVTU) in Q1 2020, closing a stake of 680,000 shares — an estimated $16.9M sold.

Eventide Asset Management first reported a position in IMVTU in Q4 2019 and held it in 1 quarter. The position peaked at $16.9M in Q4 2019. 6 funds tracked by Wall St. Rank hold IMVTU as of Q1 2020.

  • Eventide Asset Management reported no remaining Immunovant, Inc. Units position as of Q1 2020 after selling out during the quarter.
  • Eventide Asset Management sold 680,000 Immunovant, Inc. Units shares in Q1 2020, an estimated $16.9M.
  • Eventide Asset Management first reported a position in Immunovant, Inc. Units in Q4 2019 and held it in 1 quarter.
  • Eventide Asset Management's Immunovant, Inc. Units position peaked at $16.9M in Q4 2019.
  • 6 funds tracked by Wall St. Rank held Immunovant, Inc. Units as of Q1 2020.

Based on Eventide Asset Management's 13F filing for Q1 2020, filed 15 May 2020.